Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Suxamethonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.95 |
| ▸ | MAPT | P10636 | 1/20 | 0.91 |
| ▸ | BLM | P54132 | 1/20 | 0.91 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | GALR3 | O60755 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.62 |
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Suxamethonium SCHEMBL41537 | 0.97 | ADRA2A (1.00) | ADRA2AADRA1AMAPTBLML3MBTL1 | |
| Suxamethonium SCHEMBL16320883 | 0.95 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLML3MBTL1 | |
| Suxamethonium SCHEMBL21356923 | 0.95 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLML3MBTL1 | |
| Suxamethonium SCHEMBL2821312 | 0.95 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLML3MBTL1 | |
| Suxamethonium SCHEMBL41536 | 0.95 | MAPT (1.00) | ADRA2AADRA1AMAPTBLML3MBTL1 | |
| Suxamethonium SCHEMBL2690356 | 0.95 | ADRA2A (0.95) | ADRA2AADRA1AMAPTBLML3MBTL1 | |
| Suxamethonium SCHEMBL20815392 | 0.93 | MAPT (0.95) | ADRA2AADRA1AMAPTBLML3MBTL1 | |
| Suxamethonium SCHEMBL1983256 | 0.93 | MAPT (0.95) | ADRA2AADRA1AMAPTBLML3MBTL1 | |
| Bromide SCHEMBL8614700 | 0.89 | ADRA2A (0.75) | ADRA2AADRA1AMAPTBLML3MBTL1 | |
| SCHEMBL12560604 | 0.89 | ADRA2A (0.83) | ADRA2AADRA1AMAPTBLML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2024160846-A1 | ENGINEERED ALCOHOL DEHYDROGENASE FOR HIGHER ALKANOLS | UNIVERSIDADE NOVA DE LISBOA (PT) | 2024-08-08 | — | — | WO | disclosed |
| EP-3318543-B1 | METHOD FOR PRODUCING ORGANIC COMPOUND | M TECHNIQUE CO LTD (JP) | 2021-11-17 | — | — | EP | disclosed |
| CN-107683272-B | Method for producing organic compound | M技术株式会社 | 2021-10-29 | — | — | CN | disclosed |
| US-20200197310-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10583086-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-10287232-B2 | Method for producing an organic compound in a rotating forced thin-film microreactor | M. TECHNIQUE CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | NANOEGG RESEARCH LABORATORIES, INC. (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3456353-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | Nanoegg Research Laboratories, Inc. (JP) | 2019-03-20 | — | — | EP | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0737066-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1994016703-A1 | CICLOBENZAPRINE-CAFFEINE COMBINATION AS A MUSCLE RELAXANT | MERCK & CO., INC. (US) | 1994-08-04 | — | — | WO | disclosed |
| US-4571403-A | Antianginal medicated compound | INSTITUT ORGANICHESKOI KHIMII IMENI N.D. ZELINSKOGO AKADEMII NAUK SSSR (SU) | 1986-02-18 | — | — | US | disclosed |
| US-4060652-A | Nondepolarizing muscle relaxant | KHROMOV BORISOV NIKOLAI VASILI | 1977-11-29 | — | — | US | disclosed |
| US-4029800-A | 2-(4-PYRIDYL)-1,3-DIOXOLANE METHIODIDE OR 2-(1-METHYL-4-PIPERIDYL)-1,3-DIOXOLANE HYDROIODIDE | BRISTOL-MYERS COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | CHRM3, ACHE, CHRNB1 | ADRA2A 110/4885ADRA1A 54/4885MAPT 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.